Related coverage linked through entity extraction aliases.
Aug 06, 2026
FBT biotech ETF is up 20.35% YTD and 53.20% over one year, beating category averages and IBB. Its concentrated equal-weight 30-stock portfolio carries a 0.55% expense ratio and $2.9B AUM.
Apr 29, 2026
Q4 earnings were mixed across 17 tracked pharmaceutical companies. Elanco and ANI Pharmaceuticals beat revenue estimates, while Corcept and Amphastar missed. The XPH pharma ETF posted a 29% one-year return but significantly lagged the S&P 500 over five and ten years.
Apr 24, 2026
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
Apr 14, 2026
Corcept Therapeutics executives and directors were sued over alleged misstatements about a drug candidate’s approval prospects. The suit says insider stock sales totaled $97 million while the stock price was artificially inflated.
Mar 01, 2026
Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.
